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ABSTRACT
Over the last few years, several reports on the safety of antidepressants use in pregnancy have been published. Studies concern-
ing the adverse effects of exposure to selective serotonin reuptake inhibitors (SSRI) during pregnancy on the developing foetus 
have indicated an increased risk of various congenital malformations and untoward effects such as poor neonatal adaptation 
syndrome or persistent pulmonary hypertension, but there still remain inconsistencies between various study results. This paper 
aims at reviewing the literature on the risks of exposure to antidepressants during pregnancy. SSRIs are generally considered 
as first-line antidepressant treatment in pregnancy, as they are generally safe and effective. To minimize the teratogenic risks, 
pregnant women should receive the minimal effective dose of the medication. Depression during pregnancy must not be left 
untreated, and it should also be remembered that the condition may extend into the postpartum period. 
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INTRODUCTION
Affective disorders are amongst the most common 
mental health problems in women of childbearing po-
tential. A life-changing situation such as pregnancy may 
trigger or intensify the symptoms of depression. Based on 
a systematic review of published studies, it was estimated 
that around 18% of women suffer from prenatal depression, 
while in around 19% of females the symptoms emerge 
within the first several weeks following delivery [1]. Failure 
to diagnose the disease has a negative impact both on 
the mother and the baby. It was indicated that depression 
was associated, inter alia, with pre-eclampsia, premature 
birth, low birth weight, failure to seek prenatal care, in-
adequate diet, harmful substance abuse and higher risk 
of hospitalization in neonatal intensive care unit [2, 3]. It 
was also found that untreated maternal depression during 
pregnancy may lead to disturbed emotional development 
of the newborn, and may increase the risk of mental disor-
der in the future [4]. Moreover, cases of decreased density 
of grey matter were described in young children whose 
mothers had suffered from depression while pregnant [5]. 
Importantly, prenatal depression is challenged by a high 
frequency of suicidal attempts, reaching 20% in adolescent 
mothers [6]. Efficacious treatment of depression during 
pregnancy and puerperium prevents the above-mentioned 
events. Psychotherapy is the first-line treatment for mild 
to moderate depression and should be recommended to 
women who have access to a skilled practitioner, are willing 
to participate in psychotherapy sessions and for whom psy-
chotherapy is financially available. However, in women with 
Major Depressive Disorder (MDD), especially with suicidal 
thoughts, pharmacotherapy should be introduced. Accord-
ing to the guidelines on the treatment of MDD during the 
perinatal period, published in 2009 by the American Asso-
ciation of Obstetricians and Gynaecologists, monotherapy 
and taking the lowest effective dose of antidepressants 
are recommended [7]. There are no antidepressant drug 
efficacy trials in depressed pregnant women, however, 
selective serotonin reuptake inhibitors (SSRIs) are the most 
frequently used in pregnant women. In Poland, there are 
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six active substances (fluoxetine, fluvoxamine, sertraline, 
paroxetine, citalopram and escitalopram) registered, be-
longing to this group. However, it should be stressed, that 
each of them has many generics, which are available on 
the market under various names (for example, there are 
currently 17 drugs containing citalopram in the Register of 
Medicinal Products). Serotonin–norepinephrine reuptake 
inhibitors (SNRIs) have been used increasingly as an alter-
native to SSRIs in recent years [8]. The most popularly used 
SNRIs are venlafaxine and duloxetine. All the medicine 
belonging either to SSRIs or SNRIs are classified in Food 
and Drug Administration (FDA) pregnancy category C, with 
the exception of paroxetine, which is classified in D. Less 
is known about other available antidepressants (including 
bupropion, mirtazapine, trazodone or tricyclic antidepres-
sants). However, it should be stressed, that FDA categories 
are based on the assessment of risk, as obtained in hu-
man and animal studies. Categories may not directly cor-
respond with clinical safety but may simply result from the 
fact that human safety data are lacking. Moreover, drugs in 
the same category may differ in their risks to the foetus. For 
this reason in 2015 the FDA introduced new labelling, which 
contains three principal components: a clinical considera-
tion section, a risk summary and a data section.
Over recent years, the number of pregnant patients on 
antidepressants has been on the increase, but there is still 
insufficient data to be able to unequivocally determine the 
risk of birth defects and other adverse effects associated 
with the use of antidepressant medications. Potential com-
plications associated with SSRIs and SNRIs use in pregnancy 
include inter alia modest increased risk of spontaneous 
abortion, preterm birth and low birth weight, poor neonatal 
adaptation syndrome and persistent pulmonary hyperten-
sion [9]. Many studies show that a high proportion of women 
treated for depression discontinue treatment once they 
become pregnant due to safety concerns [10]. Moreover, the 
relapse rate of 68% in women with MDD who discontinued 
their drugs during the first trimester was reported [11]. The 
decision about using antidepressants during pregnancy 
must be precisely discussed with pregnant women. Selec-
tive serotonin reuptake inhibitors (SSRIs) are believed to 
manifest the most favourable risk-benefit balance, and are 
thus most commonly used in the treatment of depression, 
including the management of depression during pregnancy. 
According to a population based study, the most commonly 
prescribed SSRIs during pregnancy were drugs containing 
sertraline, citalopram, escitalopram and fluoxetine. Venla-
faxine was most commonly used SNRI [12]. To date, they 
have been treated as a homogenous class of drugs in terms 
of their teratogenic potential, but over the past year, results 
of two studies have been published in the British Medical 
Journal, indicating a possible association between the use 
of some SSRIs in the first trimester and selected congenital 
malformations [13, 14]. 
This paper aims at presenting the current state of know- 
ledge on the effect of antidepressants on foetal develop-
ment and neonatal health. 
ANTIDEPRESSANT USE AND THE RISK OF 
CONGENITAL ANOMALIES
The results of studies on the rate of major birth de-
fects and antidepressant use in pregnancy are conflicting 
and inconsistent. Many studies show no direct association 
between the use of antidepressants and birth defects, es-
pecially cardiovascular malformations.  The largest amount 
of available data concerns the safety of SSRIs, which are 
presently the most commonly used antidepressant medica-
tions [15]. The teratogenic effect of SSRIs may result from 
the direct impact of serotonin on the foetus. It plays a sig-
nificant role in the differentiation of the myocardial cells and 
formation of the cardiac septa, which is why an increased 
amount of the neurotransmitter, resulting from the use of 
drugs that inhibit its reuptake, may be linked to cardiovas-
cular defects [16]. Even though the drugs from that class all 
have similar indications and mechanisms of action, recent 
observations go to show that their teratogenic potential 
may be different (Tab. 1, 2). Fluoxetine and paroxetine are 
believed to be associated with the highest risk of birth 
defects [13, 14]. However, the available information makes 
unequivocal assessment of the teratogenic effect of anti-
depressants impossible. Further observations are required, 
as is continued monitoring of drug-related adverse events. 
In 2005, based on the available findings at the time, the 
FDA demanded that paroxetine be reclassified from preg-
nancy category C to D, i.e. a stronger warning, in recognition 
of the evidence for the drug’s risk to the foetus [17]. An ob-
servational study carried out in Canada, involving 1403 fe-
males, assessed the safety of paroxetine and other anti-
depressants. The mean dose administered was 22.4 g/day 
(27% of the patients reduced their dose immediately upon 
pregnancy confirmation, without consulting it with the 
attending physician), and the mean treatment duration 
was 64 days. Congenital anomalies were reported in 7.2% 
of the neonates born to mothers who had been using an-
tidepressants during pregnancy (39% of all study subjects 
were on paroxetine), with cardiac defects affecting 1.8 % of 
them [18]. In a detailed analysis, it was demonstrated that 
birth defects occurred in 8% of the newborns who had been 
exposed to paroxetine prenatally, as compared to 6% of 
those exposed to different SSRIs or other antidepressants, 
whereas congenital heart defects developed in 2% and 1% 
of the newborns, respectively. It was thus demonstrated 
that the use of paroxetine, dosed at over 25 mg/day, caused 
a statistically significant doubling of the risk of birth defects, 
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including a triple high risk of cardiac defects. However, other 
studies indicate, that the risk of heart defects is low [19]. In 
a recently published analysis, encompassing a literature re-
view and data from the United States National Birth Defects 
Prevention Study (NBDPS), a statistically significant associa-
tion was demonstrated between the use of paroxetine in 
the first trimester of pregnancy and the occurrence of five 
out of the seven birth defects analysed (anencephaly, atrial 
septal defect, right ventricular outflow tract obstruction, 
omphalocele, and gastroschisis) [13]. It was demonstrated 
that the absolute risk of anencephaly, when on paroxetine in 
early pregnancy, rises from 2 to 7 per 10,000 births, and the 
risk of right ventricular outflow tract obstruction from 10 to 
24 per 10,000 births. It was also confirmed that exposure to 
Table 1. Studies which confirm an association between the use of SSRIs in the first trimester of pregnancy and an increased risk of birth defects 
(according to Byatt et al. [2])
Publication Study drug/drugs
Number of subjects 
on the study drug/ 
/drugs
Results 
Wogelius et al. (2006) fluoxetine, citalopram, paroxetine, sertraline 1051
Increased risk of congenital anomalies, no association 
between the use of SSRIs and development of specific 
defects
Kallen, Otterbla, 
Olausson (2007)
citalopram, sertraline, fluoxetine, 
paroxetine 6555
Increased risk of congenital heart defects in children 
exposed to paroxetine 
Cole et al. (2007) paroxetine 1835 Increased number of birth defects
Louik et al. (2007)
fluoxetine, citalopram, paroxetine, 
sertraline, fluvoxamine, venlafaxine, 
escitalopram, bupropion
9849
Increased risk of craniosynostosis and cardiac septal 
defects in children exposed to sertraline; increased risk 
of right ventricular outflow tract obstruction 
Berard et al. (2007) paroxetine, sertraline, citalopram, fluoxetine, fluvoxamine, bupropion 1403
Increased risk of major birth defect in children exposed 
to paroxetine at the dose exceeding 25mg/day
Alwas et al. (2007) citalopram, sertraline, fluoxetine, paroxetine 9622
Increased risk of anencephaly, craniosynostosis, and 
omphalocele
Merlob et al. (2009)
sertraline, fluoxetine, paroxetine, 
fluvoxamine, citalopram, 
escitalopram
235 Two-fold increase in the risk of asymptomatic congenital heart defects in children exposed to SSRIs
Pedersen et al. (2009) fluoxetine, citalopram, paroxetine, sertraline 1370
Increased risk of cardiac septal defects in children 
exposed to sertraline and citalopram. 
Reis and Kallen (2010) SSRI, bupropion, trazodone, venlafaxine, TCA, MAOI 15017
Increased risk of birth defects in children exposed 
to TCAs (clomipramine in particular) and fluoxetine, 
increased risk of congenital heart defects in those 
exposed   to paroxetine, increased risk of hypospadias  
in those exposed to SSRIs (paroxetine in particular),  
and increased risk of  polycystic kidneys in children 
exposed to SSRIs
Bakker et al. (2010) paroxetine 678 Increased risk of cardiac septal defects
Bakker et al. (2010) fluoxetine 178 Increased risk of congenital hypertrophic pyloric stenosis  
Kornum et al. (2010)
sertraline, fluoxetine, fluvoxamine, 
paroxetine, citalopram, 
escitalopram
2062
Increased risk of birth defects, including congenital 
cardiac anomalies; increased risk of atrial septal defects 
in those exposed to sertraline 
Malm et al. (2011) fluoxetine, citalopram, paroxetine, sertraline, escitalopram 6881
Increased risk of ventricular defects in children exposed 
to fluoxetine; increased risk of right ventricular outflow 
tract obstruction in children exposed to paroxetine; 
increased risk of neural tube defects in those exposed 
to citalopram
Reefhuis et al. (2015) fluoxetine, citalopram, paroxetine, sertraline, escitalopram 659
Increased risk of right ventricular outflow tract 
obstruction and craniosynostosis following exposure to 
fluoxetine; increased risk of anencephaly, atrial septal 
defects, right ventricular outflow tract obstruction, 
omphalocele and gastroschisis following exposure to 
paroxetine
Furu et al. (2015)
sertraline, fluoxetine, fluvoxamine, 
paroxetine, citalopram, 
escitalopram, venlafaxine
1357
Exposure to venlafaxine and SSRIs (with the exception 
of escitalopram) linked to an increased risk of congenital 
cardiac anomalies  
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paroxetine was associated with atrial septal defects, ompha-
locele, and gastroschisis. Apart from the assessment of the 
teratogenic effect of paroxetine, the study also considered 
the safety profiles of four other SSRIs, including citalopram, 
escitalopram, fluoxetine and sertraline. 17952 mothers of 
children with birth defects were identified, and 9857 moth-
ers who had given birth to healthy children in the years 
1998–2009. Their use of SSRIs was confirmed based on a tele-
phone interview, carried out 6 weeks to 2 years after delivery. 
The questions asked did not refer to depression specifi-
cally, but only to the medications taken from 3 months prior 
to pregnancy up to the moment of delivery. Only those 
women who admitted to having used an SSRI at least once 
in the period from 1 month prior to conception up to the 
third month of gestation were included in the study. Lack 
of exposure to SSRIs was defined as not using them in the 
period starting from 3 months prior to conception to the 
end of pregnancy, with no diagnosis of depression, anxi-
ety, bipolar affective disorder, and obsessive-compulsive 
disorder at the time. Due to the documented teratogenic 
effect, the analysis excluded diabetic patients as well as 
women on selected medications, including misoprostol, 
methotrexate, mycophenolate mofetil, thalidomide, and 
isotretinoin. The final analysis included 17293 non-exposed 
children with birth defects, 659 exposed children with birth 
defects, 9559 non-exposed healthy children (control group) 
and 298 exposed healthy children (control group). The study 
results indicated that apart from paroxetine, also fluoxetine 
use in the first trimester of pregnancy was associated with 
the highest risk of congenital defects. Children exposed to 
fluoxetine during the first trimester were diagnosed with 
statistically significantly more atrial septal defects, right ven-
tricular outflow tract obstruction, and craniosynostosis. Im-
portantly, right ventricular outflow tract obstruction in chil-
dren whose mothers were on fluoxetine or paroxetine in early 
pregnancy had previously been reported [20]. Additionally, 
cases of anencephaly [19] and atrial septal defects [21] had 
been reported following exposure to paroxetine. 
An important finding from the above-mentioned study 
was the confirmation of a lack of association between ser-
traline use and anencephaly, anal atresia, septal defects, 
omphalocele and any limb reduction. Interestingly, as much 
as 40% of the respondents pointed out the use of that medi-
cation during pregnancy. Moreover, no association between 
maternal use of citalopram and escitalopram and ventricular 
septal defects, cleft lip with or without cleft palate, hypospa-
dias, septal defects, except for a nonsignificant association 
between citalopram and neural tube defects, was found [13].
On the other hand, in a population-based cohort study, 
in which the safety of sertraline use in the first trimester of 
pregnancy was analysed based on the data collected from 
18.5 thousand women, it was demonstrated that the risk 
of giving birth to a child with atrial or ventricular septal 
defect increased by 34%, and the risk of craniosynostosis 
doubled [22].
In other studies, escitalopram was found to be linked 
with lower birth weight, but no such association was demon-
strated for birth defects [23]. Individual cases of arhinia [24] 
Table 2. Studies which do not confirm an association between the use of SSRIs in the first trimester of pregnancy and an increased risk of birth 
defects (according to Byatt et al. [2])
Publication Study drug/drugs Number of subjects on study drug/drugs Results 
Wen SW et al. (2006) fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine 972
No association between the 
studied SSRIs and the risk of 
malformations
Cole et al. (2007) bupropion 1213 No impact on the risk of malformations
Einarson et al. (2008) paroxetine 3379
No impact on the risk of 
congenital cardiovascular 
anomalies
Ramos et al. (2008)
SSRI, TCA, SNRI, bupropion, 
mirtazapine, maclobemide, 
trazodone, nefazodone
2329 (189 with major birth 
defects)
No association between major 
birth defects and exposure to 
antidepressants
Wisner et al. (2009) SSRI 71
No association between minor 
and major birth defects and 
exposure to SSRIs
Einarson et al. (2009) (2011) SSRI, bupropion, nefazodone, trazodone, venlafaxine 928
No association between exposure 
to SSRIs and birth defects
Einarson et al. (2011) SSRI, bupropion, nefazodone, trazodone, venlafaxine 1243
No association between exposure 
to SSRIs and birth defects
Kleiger-Grossman  et al. (2011) escitalopram 212 No association between exposure to escitalopram and birth defects
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and necrotising enterocolitis [25] were described in the 
newborns exposed to prenatal escitalopram. Still, a great 
majority of the available studies demonstrate no associa-
tion between birth defects and escitalopram used during 
pregnancy [26].
A study based on the EUROCAT register (European Sur-
veillance of Congenital Anomalies), including data on 2.1 mil-
lion births in the years 1995–2009, demonstrated a link 
between the use of SSRIs in the first trimester of pregnancy 
and an increased risk of congenital heart defects (including 
tetralogy of Fallot, ToF). No differences were observed in 
terms of the teratogenic potential of the different SSRIs un-
der analysis. However, the incidence of non-cardiac defects 
was found to be variable, depending on the medication 
used. Gastroschisis was found to correspond with most 
SSRIs, with the exception of paroxetine.  Renal dysplasia was 
more common in children born to mothers on fluoxetine, 
and hypospadias was most strongly correlated with citalo-
pram. Congenital lower limb deformity was associated with 
exposure to paroxetine, sertraline and escitalopram [27]. 
However, metanalysis of prospective cohort studies, 
published in 2015, found no association between SSRI use 
in the first trimester and heart defects [28].
An analysis involving a small group of patients (77) 
indicated that the use of venlafaxine, an antidepressant 
whose toxicity profile is similar to SSRIs, was associated 
with an increased risk of birth defects such as anencephaly, 
cleft palate, gastroschisis, and atrial septal defects, among 
others [29]. A cohort study carried out in the populations 
of Nordic countries (Denmark, Finland, Iceland, Norway 
and Sweden), based on a national health registry run in 
1996–2010, also provided alarming data on the use of ven-
lafaxine and SSRIs in the first trimester of pregnancy. The 
study group involved 2.3 million women in childbirth, with 
the group of siblings including 2288 live births. The analysed 
siblings constituted a group of children born to the same 
mothers. During at least one of those pregnancies, there was 
exposure to the study drugs, and birth defects were found 
in at least one of the siblings. The use of SSRIs or venlafaxine 
was confirmed based on a prescription filled within 30 days 
before the first day of the last menstruation up until the 
end of the first trimester of pregnancy (97 days following 
the last menstruation). The study aimed at determining the 
incidence of congenital heart defects. Other risk factors were 
also examined, including maternal age at delivery, calendar 
year of birth, number of prior births, smoking during preg-
nancy, gestational diabetes, and the use of others drugs. Out 
of the 36777 newborns exposed to SSRIs or venlafaxine in 
the early phases of foetal life, birth defects were found in 
1357 (3.7%) of them, as compared with 71374 (3.2%) from 
the non-exposed group (OR — 1.13, 95%CI 1.06 — 1.20). The 
siblings analysis demonstrated that the risk of the analysed 
birth defects was 1.06% (95% CI 0.91–1.24). Taking into con-
sideration cardiovascular defects only, the risk for the entire 
study group and the group of siblings was 1.5% (OR — 1.15, 
95%CI 1.05–1.26) and 1.2% (OR — 0.92, 95%CI 0.72–1.17), 
respectively. A detailed analysis of the cardiovascular de-
fects indicated that all of the studied antidepressants, with 
the exception of escitalopram, increased the risk of cardiac 
defects, when used in pregnancy. 
Another antidepressant, bupropion, is used to treat 
depressive disorders and as a smoking cessation aid. Most 
of the data on the impact of bupropion on the developing 
foetus comes from the Bupropion Pregnancy Registry da-
tabase, established by the drug’s producer. In a 2008 report, 
24 cases of birth defects were described among children 
born to 675 women who had been on bupropion in the 
first trimester of pregnancy [30]. 9 cases of congenital heart 
defects were found, including ventricular septal defects and 
coarctation of the aorta (2 cases). Analysis of the results 
generated in the CDC’s National Birth Defects Prevention 
Study (NBDPS) demonstrated no association between the 
use of bupropion and atrial septal defects, but it did confirm 
a slight increase in the risk of cardiovascular malformations, 
including coarctation of the aorta and hypoplastic left heart 
syndrome (HLHS) [31]. However, the findings were not con-
firmed in an analysis based on the Pregnancy Health Inter-
view Study, which only pointed out a slight increase in the 
risk of ventricular septal defects in children born to mothers 
on bupropion in the first trimester of pregnancy [32]. 
Analysis of the Medicaid database, including data on 
nearly 950 thousand pregnancies (from the years 2000– 
–2007), failed to demonstrate an association between the 
use of antidepressant medications (SSRIs, SNRIs, TCAs and 
bupropion) and birth defects, including congenital cardiac 
anomalies. On the other hand, the study indicated that 
women suffering from depression were significantly more 
frequently subjected to check tests such as ultrasound, 
foetal echocardiography, and amniocentesis than healthy 
women, which should be conducive to detecting even mi-
nor birth defects [33]. 
ADVERSE EFFECTS OF ANTIDEPRESSANTS 
OTHER THAN BIRTH DEFECTS REPORTED  
IN CHILDREN WITH PRENATAL EXPOSURE 
Poor neonatal adaptation syndrome (PNAS)
PNAS is a transient syndrome involving a set of symp-
toms that develop in response to foetal exposure to psycho-
tropic medications. Aetiology of the syndrome has not been 
fully explored, though. It is emphasised that its symptoms, 
resembling those of withdrawal syndrome, may occur as 
a result of discontinued exposure to the drug upon birth (all 
psychotropic drugs cross the placental barrier). It has been 
noted that the syndrome does not develop in children born 
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to mothers who take the same antidepressant drug dur-
ing pregnancy and lactation. The PNAS symptoms involve 
weakened suction reflex, irritability, poor muscle tone, weak 
cry or lack thereof, sleep disturbances, hypoglycaemia, and 
seizures. In most cases, the symptoms appear within the first 
8 hours of delivery and persist for the first 2–6 days of life. It 
is believed that the syndrome will not develop if there are no 
symptoms within the first two days of life [34]. Withdrawal 
symptoms and toxicity symptoms are largely overlapping, 
which is why differentiation based on the clinical picture 
is extremely difficult. Nevertheless, in case of toxic events, 
the symptoms emerge immediately upon delivery, and the 
drug’s concentration in the newborn’s serum is high. With-
drawal symptoms, on the other hand, appear within 8 to 
48 hours of birth, and the drug serum level is low. Many 
researchers suggest a mixed aetiology of the syndrome, 
involving both elements of toxicity and withdrawal. An 
analysis of PNAS cases among mothers treated with anti-
depressants indicated an increase in the risk of respiratory 
distress and tremor. The analysis was inconclusive as to 
which of the drugs is associated most strongly with the 
risk of PNAS in newborns, but it was established that the 
symptoms may affect from 20% to 77% of children exposed 
to SSRIs during foetal life [35]. Some of the studies also indi-
cated an increased risk linked to the use of paroxetine and 
fluoxetine [36]. When using venlafaxine, the risk of PNAS is 
comparable to that associated with the use of SSRIs [37]. 
In children with prenatal exposure to TCAs, individual 
cases of adverse events have been observed, including is-
churia and constipation, stemming from the drugs’ cholino-
lytic action. It is estimated that PNAS develops in 20–50% of 
children whose mothers receive TCAs during pregnancy [38]. 
Long-term effects of PNAS have been examined by a few 
observational studies only. No impact of PNAS on the chil-
dren’s IQ and general development has been reported [39]. 
Persistent pulmonary hypertension  
of the newborn
It is estimated that the incidence of the persistent pul-
monary hypertension of the newborn (PPHN) amounts 
to 1.9/1000 live births [40]. The symptoms are observed 
immediately upon delivery, and they may be of varying 
intensity, ranging from mild respiratory insufficiency to se-
vere respiratory failure, leading to hypoxia, and requiring 
intensive medical care. In 2006, FDA published an alert, in-
forming about the possible association between PPHN and 
prenatal SSRIs. In 2011, it was revised to include information 
on an insufficient number of findings, often contradictory, 
which made it impossible to draw unequivocal conclusions 
on the matter. In a meta-analysis published in 2014, it was 
indicated that the risk of PPHN was higher only in the case 
of SSRI use in advanced pregnancy (weeks 33–34) [41]. 
SUMMARY
In light of the available data, pregnancy should be well 
planned by women suffering from depression. Effective 
treatment of depression during pregnancy needs an ob-
stetrician’s and a psychiatrist’s coordinated care. There are 
currently no recommendations as for the pharmacologi-
cal treatment of depression in pregnancy. Each pregnant 
woman on antidepressants should thus be under continu-
ous care of a specialised psychiatrist. Both modification 
of antidepressant treatment as well as its discontinuation 
(in particular discontinuation of paroxetine) should be 
consulted with the attending psychiatrist. Antidepressant 
medications should be discontinued gradually in order not 
to risk the appearance of withdrawal symptoms. Despite 
the fact that some antidepressants (fluoxetine and parox-
etine) have been linked to an increased risk of birth defects 
[13, 14, 42], it should be remembered that depression is 
a disease which is associated with a high risk of suicide, 
which is why the decision on discontinuing the treatment 
should take into consideration the patient’s mental state. 
Moreover, some of the studies resulting in alarming findings 
on the teratogenic effect of antidepressant medications 
have failed to take into account other risk factors such as 
maternal age, and use of other drugs and stimulants. It is 
worth emphasising that the treatment of depression also 
involves psychotherapy, which is a recognized and recom-
mended therapeutic method in pregnancy. Children born 
to mothers who used antidepressants during pregnancy 
should be under special medical surveillance, including 
comprehensive diagnostics of congenital anomalies (and 
cardiac defects in particular), and should be followed up 
for the risk of PNAS. It should also be remembered that 
depression during pregnancy increases the risk of post-
partum depression. It should be stressed that more often 
the benefits for the mother exceed the potential risk for the 
neonate as a result of the use of antidepressants.
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